ArticleGut and liver2023
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Article in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Comparison of tegoprazan-based and proton pump inhibitor-based regimens forFrontiers in medicine · 2025Pooled it
- Treatment ofWorld journal of gastroenterology · 2024Pooled it
- Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.Journal of digestive diseasesPooled it
- Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders.Journal of clinical medicine · 2026Review
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Update on the pathogenesis and clinical management ofWorld journal of gastrointestinal pathophysiology · 2025Review
- Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB).European journal of clinical pharmacology · 2025Review
- Tegoprazan dual and quadruple therapy forFrontiers in medicine · 2025Article
- Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy forTherapeutic advances in gastroenterology · 2025Article
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.Current gastroenterology reports · 2024Review
- Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-LineMicroorganisms · 2024Article
- Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments forThe Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- [Current Status and Future Perspectives of Tegoprazan-BasedThe Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial.Clinical drug investigation · 2024Article
- Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?Gut and liver · 2023Article
- Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy forJournal of personalized medicine · 2022Article
- [Impact of P-CABs in the Treatment of Acid-related Diseases: an Evidence Review].Acta gastroenterologica LatinoamericanaReview
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare the Methods: We retrospectively reviewed data from patients who received first-line treatment for Results: Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604). Conclusions: The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.